David Benjamin

Oct 31, 2024 | bjui-journals.onlinelibrary.wiley.com | David Benjamin |Anshu Shrestha |Arash Rezazadeh Kalebasty |Dimitra Fellman

1 INTRODUCTION The incidence of testicular cancer has been rising globally among young adult men for the past five decades for reasons not currently well-understood.1 Although a rare genitourinary malignancy that is generally curable, testicular cancer remains a significant public health concern due to long-term medical, psychological and social burden associated with treatment and its short- and long-term toxicities.2 Risk factors leading to the development of testicular cancer include age,...

May 14, 2024 | bjui-journals.onlinelibrary.wiley.com | David Benjamin |Omid Yazdanpanah |Arash Rezazadeh Kalebasty

Research Letter A review of vitamin use for the prevention or treatment of prostate cancer David J. Benjamin,  Corresponding Author David J. Benjamin Hoag Family Cancer Institute, Newport Beach, CA, USA Correspondence: David J. Benjamin, Hoag Family Cancer Institute, 1 Hoag Drive, Building 41, Newport Beach, CA 92663, USA.

Mar 16, 2024 | onlinelibrary.wiley.com | David Benjamin |Alyson Haslam |Vinay Prasad

1 INTRODUCTION Cancer remains the leading cause of morbidity in many countries with an estimated 19.3 million new cancer cases and nearly 10.0 million deaths globally in 2020 alone.1 Despite the development and approval of therapeutics such as immune checkpoint inhibitors and drugs targeting specific oncogenic driver mutations, many individuals with cancer remain ineligible for these therapies and many cancers remain incurable.2-4 As such, cancer continues to inflict devastating financial and...

Mar 16, 2024 | dx.doi.org | David Benjamin |Alyson Haslam |Vinay Prasad

1 INTRODUCTION Cancer remains the leading cause of morbidity in many countries with an estimated 19.3 million new cancer cases and nearly 10.0 million deaths globally in 2020 alone.1 Despite the development and approval of therapeutics such as immune checkpoint inhibitors and drugs targeting specific oncogenic driver mutations, many individuals with cancer remain ineligible for these therapies and many cancers remain incurable.2-4 As such, cancer continues to inflict devastating financial and...

Dec 26, 2023 | onlinelibrary.wiley.com | Omid Yazdanpanah |Aditya Mahadevan |Aditi Sharma |David Benjamin

1 INTRODUCTION Prostate cancer composes a significant proportion of diagnosed cancers worldwide, with an incidence of over 288,000 cases annually in the United States.1 Risk factors include age, ethnicity, family history, as well as lifestyle factors including red meat consumption.2-4 The management of prostate cancer incurs significant costs, often exceeding $55,000 per person-year in patients with metastatic disease.5 Bone metastases are a common complication of patient with prostate...